Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit
Rhea-AI Summary
Kura Oncology (Nasdaq: KURA) will participate in the TD Cowen 7th Annual Oncology Innovation Summit on May 26, 2026. Management will join a virtual fireside chat at 1:30 p.m. ET / 10:30 a.m. PT, with live and archived webcasts available via the company’s investor website.
Positive
- None.
Negative
- None.
News Market Reaction – KURA
In the May 20 session, KURA gained 15.40%, reflecting a significant positive market reaction. Argus tracked a peak move of +11.0% during that session. Our momentum scanner triggered 63 alerts that day, indicating high trading interest and price volatility. Trading volume was very high at 3.3x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 12 | Q1 2026 earnings | Neutral | -2.1% | First commercial-stage quarter with KOMZIFTI revenue and higher operating expenses. |
| May 12 | Clinical data update | Positive | +1.8% | Strong KOMET-007 frontline AML data presented ahead of EHA 2026 Congress. |
| May 06 | Conference participation | Neutral | +2.9% | Participation in Bank of America Healthcare Conference fireside chat webcast. |
| May 05 | Earnings date notice | Neutral | +0.4% | Announcement of timing for Q1 2026 results and corporate update call. |
| May 04 | Equity inducement grants | Negative | +5.5% | Inducement stock option grants for new employees under 2023 Inducement Plan. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Conference and clinical data updates have generally coincided with positive price moves, while earnings and equity-related items have produced mixed reactions.
Over recent months, Kura Oncology has transitioned into a commercial-stage company with KOMZIFTI, reporting total revenue of $18.3 million and a net loss of $73.3 million in early May 2026. The company highlighted strong ziftomenib data from the Phase 1 KOMET-007 trial and announced multiple conference appearances and investor events. An inducement option grant on May 1, 2026 and proxy-related governance items added to corporate activity. Today’s summit participation fits the pattern of ongoing investor engagement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA) today announced its participation in the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Kura management is scheduled to participate in a virtual fireside chat at 1:30 p.m. ET / 10:30 a.m. PT on May 26, 2026.
The live webcast and archived replay of the event may be accessed on the Investors section of the Company’s website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™ (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Kura Contact
Greg Mann (Investors and Media)
858-987-4046
gmann@kuraoncology.com
